Strategic Initiative

Slingshot members are tracking this corporate initiative:

Insmed (INSM) and AstraZeneca (AZN) Announce Worldwide License Agreement Giving INSM Global Exclusive Rights to Develop AZD7986 in Non-Cystic Fibrosis Bronchiectasis

Source Link:: http://files.shareholder.com/downloads/INSMED/2964432481x0x910600/FB95128D-52B7-47C0-A0BB-1AE9BE55AB79/INSM_News_2016_10_5_General.pdf

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

AZN

100%

INSM

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Slingshot Insights Explained

JOIN FOR FREE TODAY

Strategic Initiative Date

Announcement Date:

Oct 05, 2016

Projected Implementation:

Q1, 2017

Relevance Tracked Until:

Q1, 2019

Related Projects

Don’t see a project related to the strategic initiative you care about?

Related Keywords Worldwide License Agreement, Global Exclusive Rights, Azd7986, Non-cystic Fibrosis Bronchiectasis